Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + Famitinib vs Pembrolizumab in PD-L1+ NSCLC
NCT05042375Phase 3Recruiting
- Sponsor
- Hengrui
- Start
- Sep 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of camrelizumab, famitinib in non-small cell lung cancer (NSCLC), sponsored by Hengrui. Started Sep 2022; status: recruiting.
02
Drugs
camrelizumabfamitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05042375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05042375.